LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 206 filers reported holding LIGAND PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.46 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,000 | -90.8% | 67 | -81.2% | 0.00% | -88.9% |
| Q3 2018 | $98,000 | +32.4% | 357 | 0.0% | 0.03% | +17.4% |
| Q2 2018 | $74,000 | -97.2% | 357 | -97.8% | 0.02% | -97.2% |
| Q1 2018 | $2,638,000 | +27.8% | 15,970 | +5.9% | 0.83% | +23.0% |
| Q4 2017 | $2,064,000 | +3.3% | 15,075 | +2.7% | 0.68% | -6.9% |
| Q3 2017 | $1,999,000 | +16.0% | 14,680 | +3.4% | 0.73% | +6.3% |
| Q2 2017 | $1,724,000 | +16.3% | 14,204 | +1.4% | 0.68% | +14.2% |
| Q1 2017 | $1,483,000 | +9.1% | 14,011 | +4.8% | 0.60% | -6.5% |
| Q4 2016 | $1,359,000 | +3.3% | 13,374 | +3.7% | 0.64% | -3.5% |
| Q3 2016 | $1,316,000 | +29.8% | 12,896 | +51.8% | 0.66% | +27.6% |
| Q2 2016 | $1,014,000 | +20.9% | 8,498 | +8.5% | 0.52% | +1.4% |
| Q1 2016 | $839,000 | -36.2% | 7,832 | -35.4% | 0.51% | -57.3% |
| Q4 2015 | $1,315,000 | +32.4% | 12,127 | +4.6% | 1.20% | +1.9% |
| Q3 2015 | $993,000 | -15.9% | 11,599 | -0.9% | 1.18% | +4.4% |
| Q2 2015 | $1,181,000 | – | 11,708 | – | 1.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |